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ABSTRACT
Mesoangioblasts have been characterized as a population of
vessel-associated stem cells able to differentiate into several
mesodermal cell types, including skeletal muscle. Here, we
report that the paired box transcription factor Pax3 plays a
crucial role in directing mouse mesoangioblasts toward skel-
etal myogenesis in vitro and in vivo. Mesoangioblasts iso-
lated from the aorta of Pax3 null embryos are severely
impaired in skeletal muscle differentiation, whereas most
other differentiation programs are not affected by the ab-
sence of Pax3. Moreover, Pax3/ null mesoangioblasts
failed to rescue the myopathic phenotype of the -sarco-
glycan mutant mouse. In contrast, mesoangioblasts from
Pax3 gain of function, Pax3PAX3-FKHR/, mice display en-
hanced myogenesis in vitro and are more efficient in
regenerating new muscle fibers in this model of muscular
dystrophy. These data demonstrate that Pax3 is required
for the differentiation of mesoangioblast stem cells into
skeletal muscle, in keeping with its role in orchestrating
entry into the myogenic program. STEM CELLS 2009;27:
157–164
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Mesoangioblasts are vessel-associated stem cells that can self-
renew and are able to differentiate into several types of meso-
dermal tissues such as smooth, cardiac, and skeletal muscle,
bone, and fat, when treated with the appropriate signaling mol-
ecules or cocultured with differentiating cells of the same tissue
[1]. When delivered through the arterial circulation, mesoangio-
blasts cause a significant structural and functional improvement
in different animal models of muscular dystrophy [2, 3]. More
recently, cells with similar properties have been isolated from
biopsies of postnatal human skeletal muscle. These cells, which
express markers of pericytes, were also shown to differentiate
into skeletal muscle in vitro and to ameliorate the dystrophic
phenotype when delivered intra-arterially into the muscle of
mdx-SCID dystrophic mice [4]. Although the myogenic poten-
tial of mesoangioblasts has been demonstrated in vitro and in
vivo, the molecules regulating this process are still unknown.
Genome-wide RNA expression analysis, performed on mesoan-
gioblasts, revealed a characteristic pattern of expression that
correlates with the biological features and the developmental
potency of these cells [5]. Mesoangioblasts were found to ex-
press Pax3 at a high level. The paired box/homeodomain tran-
scription factors of the Pax family play important roles in the
formation of tissues and organs during embryonic development
[6]. In particular, Pax3 is implicated in neurogenesis in regions
of the central nervous system, regulates neural crest and its
derivatives, and plays a key role in skeletal myogenesis. In the
latter context, Pax3 is expressed in paraxial mesoderm and
marks multipotent cells of the dorsal somite, the dermomyo-
tome, from which skeletal muscle is derived. Endothelial and
smooth muscle cells are also derived from paraxial mesoderm,
and the same Pax progenitor in the dermomyotome can give
rise to both the smooth muscle cells of blood vessels and
skeletal muscle [7, 8]. During the first wave of early myogen-
esis, Pax3 is required for the survival of cells in the hypaxial
dermomyotome and their migration to sites outside the somite.
Subsequently, in the limb buds, for example, it directly activates
the myogenic determination gene Myf5 [9]. Transcriptional ac-
Author contributions: G.M.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing;
D.S.: conception and design, collection and assembly of data, data analysis and interpretation; G.M. and D.S. contributed equally to this work;
S.M.: collection of data; B.G.: collection of data; E.S.: collection of data; R.T.: provision of study material; L.D.A.: collection of data; S.B.:
collection of data; F.R.: provision of study material; M.B.: conception and design, manuscript writing, financial support; G.C.: conception
and design, manuscript writing, financial support.
Correspondence: Giulio Cossu, M.D., Stem Cell Research Institute, Dibit, H. San Raffaele, via Olgettina 58, 20132 Milan, Italy. Telephone:
3902-2643-4954; Fax: 3902-2643-4621; e-mail: cossu.giulio@hsr.it Received May 22, 2008; accepted for publication September 28, 2008;
first published online in STEM CELLS EXPRESS October 9, 2008. ©AlphaMed Press 1066-5099/2008/$30.00/0 doi: 10.1634/stemcells.2008-
0503
TISSUE-SPECIFIC STEM CELLS
STEMCELLS 2009;27:157–164 www.StemCells.com
tivity of Pax3 itself, which also impacts MyoD, is regulated in
the somite by noncanonical Wnt signaling from the dorsal
ectoderm [10]. In addition to Myf5, Pax3 directly activates
myogenic expression of Fgfr4, and also lies genetically up-
stream of Sprouty1 [11], which encodes an intracellular inhibitor
of this signaling pathway, thus modulating the balance [12]
between progenitor cells and their entry into the myogenic
program that is promoted by fibroblast growth factor signaling
[11]. Subsequent myogenesis depends on a population of pro-
genitor cells that originates from the central domain of the
dermomyotome where Pax7 as well as Pax3 are present. These
cells provide a reserve of resident stem cells, within the devel-
oping muscle masses, where they constitute a self-renewing
population that also differentiates into muscle fibers [13–15].
Lack of both Pax3 and Pax7 causes a major muscle deficit
during late embryonic development; many progenitor cells die
or change fate, in the absence of Myf5, Mrf4, and MyoD acti-
vation [15]. These three myogenic factor genes are essential at
this stage for determining muscle cell fate. A fourth member of
this family of basic helix-loop-helix transcription factors, myo-
genin, acts as a differentiation factor, controlling downstream
muscle genes, such as those encoding myosin heavy chains
(MHCs). The population of Pax3/Pax7 cells from the central
dermomyotome later gives rise to satellite cells, the progenitor
cells of postnatal muscle. Pax7 plays a key role in these cells
[16], ensuring their survival [17], whereas both Pax7 and Pax3,
expressed in a subset of satellite cells, control MyoD activation
and satellite cell myogenesis.
In this report, we studied the role of Pax3 in the myogenic
differentiation of mesoangioblasts. We generated mesoangio-
blasts from Pax3 null embryos as well as from mice expressing
a constitutively active form of Pax3, Pax3-FKHR [18]. Our
analysis shows that Pax3, but not Pax7, regulates the differen-
tiation of mesoangioblasts into skeletal muscle. This is consis-
tent with the paraxial mesoderm origin of these cells in the
embryonic dorsal aorta [8] and underlines the key role of Pax3/
Pax7 in controlling the entry of cells into the myogenic program.
MATERIALS AND METHODS
Isolation and Culture of Pax3 Null and PAX3-FKHR
Mesoangioblasts
Pax3 null and PAX3-FKHR mesoangioblasts were generated from
the dorsal aorta of Pax3GFP/GFP and Pax3PAX3FKHR-IRESnLacZ/
mouse embryos (embryonic day, 9.5), respectively [15, 18]. Cells
were isolated, cloned, and expanded as described previously [19].
The well-characterized D16, D15, and D53 clones of mouse me-
soangioblasts were cultured as described previously [1, 20]. Human
satellite cells, used in the cocultures, were cultured as described
[21].
Differentiation Assays
Differentiation into smooth muscle cells and osteoblasts was in-
duced by treatment with transforming growth factor (TGF)1 and
bone morphogenic protein (BMP)2, respectively, and analyzed as
previously described [1, 5]. For mineralized nodule assays, mesoan-
gioblasts were maintained in growth medium supplemented with 50
g/ml ascorbic acid, 10 mM -glycerol phosphate, dexamethasone
10–8 M, and 100 ng/ml BMP2 for 25 days. At the end of the culture
period, cultures were stained for alkaline phosphatase, and mineral
deposition was assessed using the von Kossa method, according to
the standard procedure.
Differentiation into skeletal muscle was induced by coculturing
murine mesoangioblasts with human myoblasts at a 1:10 ratio. To
induce muscle fiber formation, cultures were shifted to differentia-
tion medium (Dulbecco’s modified Eagle’s medium supplemented
with 2% horse serum). After 7 days, cultures were stained with
antibodies against striated MHC (MF20) and lamin A/C, which
stains the human nuclei. The percentage of mesoangioblast myo-
genic differentiation was calculated by counting the number of
murine 4,6-diamidino-2-phenylindole (DAPI) (lamin A/C) nu-
clei within myosin-positive cells as a percentage of total DAPI
(lamin A/C) nuclei. Biochemical differentiation was confirmed by
reverse transcription-polymerase chain reaction (RT-PCR) using
mouse specific oligonucleotides for MyoD and myogenin tran-
scripts. Skeletal myogenesis of PAX3-FKHR expressing mesoan-
gioblasts was induced by plating cells onto Matrigel-coated dishes
in differentiation medium. After 7 days, cultures were fixed and
stained with antibodies against striated myosin (MF20) and MyoD.
Immunoblotting
Western blotting analysis of cells or tissues was performed as
described [22]. The antibodies used were: anti-Pax3 (Hybridoma
Bank, Iowa City, IA, http://dshb.biology.uiowa.edu), mouse anti--
sarcoglycan (-SG) (Novocastra Ltd., Newcastle upon Tyne, U.K.,
http://www.novocastra.co.uk), mouse anti--tubulin (Covance,
Princeton, NJ, http://www.covance.com), and anti-MHC (MF20,
Hybridoma Bank).
Immunofluorescence
Cells were washed with phosphate-buffered saline and fixed with
4% paraformaldehyde for 10 minutes. Muscle samples from me-
soangioblast-transplanted -SG null mice were frozen in liquid
nitrogen cooled isopentane, and serial 8-m thick sections were cut
with a Leica cryostat (Leica Microsystems GmbH, Wetzlar, Ger-
many, http://www.leica-microsystems.com). Cells and tissue sec-
tions were processed for immunofluorescence as previously de-
scribed [2]. The antibodies used were: mouse anti-smooth muscle
actin (Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com),
rabbit anti-green fluorescent protein (GFP) (Molecular Probes Inc.,
Eugene, OR, http://probes.invitrogen.com), anti-MHC (MF20; Hy-
bridoma Bank), mouse anti-laminin (Sigma), mouse anti-lamin A/C
(Novocastra), and anti--SG (Novocastra).
RT-PCR
RNA (1 g) collected from different mesoangioblast cultures was
converted into double-stranded cDNA by reverse transcription us-
ing the cDNA synthesis Thermoscript RT-PCR System kit (Invitro-
gen, Carlsbad, CA, http://www.invitrogen.com). cDNA was then
amplified using the following primers:
VE-cadherin (VE-Cad, 227 bp; forward [Fw], 5 gga tgc aga
ggc tca cag ag 3; reverse [Rev], 5 ctg gcg gtt cac gtt gga ct 3),
Flk1 (270 bp; Fw, 5 tct gtg gtt ctg cgt gga ga 3; Rev, 5gta tca ttt
cca acc acc ct 3), CD34 (300 bp; Fw, 5 ttg act tct gca acc acg ga
3; Rev, 5 tag atg gca ggc tgg act tc 3), c-Kit (400 bp; Fw, 5 ggc
tca taa atg gca tgc tc 3; Rev, 5 ctt cca ttg tac ttc ata cat g 3), Cbfa1
(387 bp; Fw, 5 ccg cac gac aac cgc acc at 3; Rev, 5 cgc tcc ggc
cca caa atc tc 3), bone sialoprotein (BSP, 563 bp; Fw, 5 gaa acg
gtt tcc agt cca g 3; Rev, 5 tga aac ccg ttc aga agg 3); collagen 1A2
(Coll1A2, 484 bp; Fw, 5gca atc ggg atc agt acg aa 3; Rev, 5 ctt
tca cgc ctt tga agc ca 3); osteocalcin (292 bp; Fw, 5 aag cag gag
ggc aat aag gt 3; Rev, 5 agc tgc tgt gac atc cat ac 3); osteopontin
(437 bp; Fw, 5 tca cca ttc gga tga gtc tg 3; Rev, 5 act tgt ggc tct
gat gtt cc 3); osteonectin (499 bp; Fw, 5 cac ata act ctg agg cca ttg
3; Rev, 5 gcc caa ttg cag ttg agt gat 3); MyoD (455 bp; Fw, 5ctg
ctt ttg gca gat gca cc 3; Rev, 5 cag tga ggt gca gcc aga gt 3), and
myogenin (272 bp; Fw, 5ctg ggg acc cct gag cat tg 3; Rev, 5 atc
gcg ctc ctc ctg gtt ga 3).
In Vivo Injection
Two-month-old -SG [23] null mice (injected slowly through the
entire anterior surface of the tibialis muscle with a 27-gauge needle
containing 100 l of 5 M cardiotoxin [Sigma] 12 hours before
treatment) were injected through the right femoral artery or by
intramuscular injection with 5  105 mouse mesoangioblasts (pre-
treated with stromal cell-derived factor 1 to increase cell migration),
as described in [24]. To be sure that the lack of Pax3 did not affect
cell migration, 5  105 Pax3 wild-type (wt) or Pax3 null mesoan-
gioblasts were also injected into the tibialis anterior of the -SG null
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mice. A set of animals was sacrificed after 1 week to follow
mesoangioblast migration into the muscles. A real-time PCR for
GFP was performed on all the samples as described below (see
Real-time PCR). After 1 month, different muscles (quadriceps,
gastrocnemius, and tibialis) were collected and -SG expression
was checked by Western blot analysis.
Real-Time PCR
Total RNA from muscles (gastrocnemius) and cells was isolated
using the TRIzol protocol (Invitrogen) and reverse transcribed with
the Taqman kit (Platinum Taq DNA polymerase; Invitrogen). Real-
time quantitative PCR was carried out with a real-time PCR system
(Mx3000P; Stratagene, La Jolla, CA, http://www.stratagene.com).
Each cDNA sample was amplified in duplicate using SYBR Green
Supermix (Bio-Rad, Hercules, CA, http://www.bio-rad.com) for
GFP (Fw, aagttcatctgcaccaccg; Rev, tccttgaagaagatggtgcg), glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH; Fw, 5-gatgatgac-
ccgtttggctcc-3; Rev, 5-gatgatgacccgtttggctcc-3), and LacZ (Fw,
5-actatcccgaccgccttact-3; Rev, 5-tagcggctgatgttgaactg-3). Delta
Ct values were normalized to those obtained from the amplification
of GAPDH transcripts.
For the migration assay, data are expressed as the percentage of
migrated cells, which is calculated by comparing the expression
level of the GFP reporter gene in the experimental sample with that
measured in the total input of injected cells.
Cell Transfection and Infection
The D16 mesoangioblast cell line was transfected by the liposome
Fugene (Roche Diagnostics, Basel, Switzerland, http://www.roche-
applied-science.com). In order to obtain stable transfected clones,
cells were cotransfected with the Pax3-Engrailed (Pax3-Engr) gene
plasmid and the plasmid delivering puromycin as a transfection
selection marker (ratio 5:1). The Pax3 dominant negative form was
obtained by fusing in-frame sequences encoding the Drosophila
melanogaster Engrailed repression domain (298 amino acids [24])
to the first 374 amino acids of Pax3 [16]. After 48 hours, 2 g/ml
of puromycin was added. Forty-eight hours after selection, single
clones were expanded and assayed for plasmid expression. In the
myogenin-lacZ reporter construct (kindly provided by Dr. Libera
Berghella) LacZ is under the transcriptional control of the 1.1-kb
upstream region of the myogenin promoter.
The cDNA coding for FOXO1A (FKHR) was subcloned into
the pcDNA3 expression vector (Invitrogen). Mesoangioblasts were
transfected with pcDNA3-FOXO1A or pcDNA3 alone as a control.
After 48 hours, 0.5 mg/ml of G-418 (Sigma) was added and the
selected populations were tested for muscle differentiation as de-
scribed above.
RESULTS
Generation of Pax3 Null Mesoangioblasts:
Morphology, Proliferation, and Gene Expression
To confirm data obtained by the RNA-microarray analysis [5],
we analyzed the expression of Pax3 in three well-characterized
clones of mouse mesoangioblasts (D16, D15, and D63) by
Western blot. As shown in Figure 1A, all the clones expressed
Pax3, but not Pax7. To investigate the possible role of Pax3 in
mesoangioblast commitment to the skeletal muscle fate, we
isolated these cells from the dorsal aorta of E10.5 Pax3GFP/
heterozygote and Pax3GFP/GFP null as well as wt embryos [14].
Both the wt and the Pax3 null cells showed good clonogenic
efficiency. Under normal culture conditions, Pax3 wt and Pax3
null mesoangioblasts displayed the same phenotype, morphol-
ogy (Fig. 1D), and proliferation rate (not shown). Analysis by
RT-PCR (Fig. 1C) and examination of surface markers by flow
cytometry (not shown) showed no significant differences in
gene expression between Pax3 null and wt mesoangioblasts.
Like previously described mesoangioblast clones [1], both wt
and Pax3 null mesoangioblasts were found to express CD34,
CD31, VE-Cad, and Sca-1. In addition, although GFP expres-
sion was progressively extinguished with passage in culture, the
presence of the reporter gene was still detectable by RT-PCR in
the Pax3 null cells (Fig. 1B).
Pax3 Null Mesoangioblasts Fail to Differentiate into
Skeletal Muscle
We tested the ability of Pax3 null mesoangioblasts to differentiate
into different mesodermal cell types using assays previously de-
scribed [1].
Following TGF treatment, both wt and Pax3 null mesoan-
gioblasts (selected clones and the polyclonal populations) dif-
ferentiated at a high frequency into smooth muscle (Fig. 2A).
Treatment of Pax3 null mesoangioblasts with BMP2, normally
used to induce the osteogenic program, led to bone differentia-
tion similar to that in wt cells, as revealed by the analysis of
osteogenic markers, such as BSP, osteopontin, osteonectin, and
osteocalcin (Fig. 2B), by RT-PCR. Moreover, when cultured in
the presence of dexamethasone, ascorbic acid, and -glycero-
phosphate, Pax3 null mesoangioblast clones gave rise to von
Kossa-positive bone-like nodules in vitro with the same effi-
ciency (8%) as their wt counterparts (10%) (Fig. 2C), although
Figure 1. Morphology, proliferation, and gene expression profile of
Pax3 null mesoangioblasts. (A): Pax3 and Pax7 expression in three
different well-characterized clones of mouse mesoangioblasts, D16,
D15, and D63. -tubulin was used to normalize the amount of proteins
loaded. (B): Expression of the reporter gene GFP in the Pax3 null
mesoangioblasts by RT-PCR. (C): RT-PCR of the markers normally
expressed in wt mesoangioblasts in comparison with Pax3 null cells.
C (a total embryo extract) was used as a positive control. (D): Phase
contrast images of Pax3 null mesoangioblasts (Pax3 null) in comparison
with wt cells (Pax3wt). Abbreviations: GFP, green fluorescent protein;
RT-PCR, reverse transcription-polymerase chain reaction; SC, satellite
cells; VE-Cad, VE-cadherin; wt, wild-type.
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alkaline phosphatase activity was greatly reduced in the mutant
cells, as shown by alkaline phosphatase staining (purple cells,
Fig. 3A). When exposed to an adipogenic medium, Pax3 null
cells were not able to differentiate into adipocytes, in compar-
ison with wt cells (Fig. 3B), thus suggesting an unexpected role
of Pax3 in adipogenic differentiation. Finally, we tested the
ability of the Pax3 null mesoangioblasts to differentiate into
skeletal muscle. Similar to wt mesoangioblasts, Pax3 null cells
did not differentiate spontaneously in vitro. To induce skeletal
muscle in vitro, we cocultured wt or Pax3 null mesoangioblasts
with human muscle satellite cells. The contribution of mouse
versus human cells to myotubes was analyzed using an antibody
that is specific for human nuclear laminin and by the analysis of
mouse or human muscle-specific gene expression by RT-PCR.
As shown in Figure 4A and B, the Pax3 null mesoangioblasts,
unlike wt cells, failed to fuse into human myotubes and to
activate skeletal muscle-specific genes. RT-PCR, performed
with mouse-specific primers for transcripts of the myogenic
factors MyoD and myogenin, amplified these messenger RNAs
in wt but not in Pax3 null cells cocultured with human myogenic
cells (Fig. 4C). To further confirm this, we transfected the D16
mesoangioblast cell line [2] with a construct expressing
Pax3Engr, where the Pax3 DNA-binding domain is fused to the
Engrailed transcriptional repression domain [25]. Previous work
demonstrated that the Pax3-Engrailed fusion protein negatively
affects myogenesis in cultured satellite cells [17]. Stable clones
expressing Pax3-Engrailed or a control vector were subse-
quently transiently transfected with a myogenin-lacZ reporter
construct, where the lacZ reporter is regulated by the myogenin
promoter, activated at the onset of myogenic differentiation.
Following 3-day culture in differentiation medium, myogenin-
lacZ expression was measured by quantitative real-time PCR.
As shown in Figure 4D, myogenin activation was reduced more
than threefold in the D16 Pax3Engr cells in comparison with
control cells. Moreover, to demonstrate that the difference in
myogenic differentiation was directly dependent upon Pax3
expression, we transiently cotransfected Pax3 null mesoangio-
blasts with Pax3-GFP and GFP expression vectors. GFP and
GFP cells were separated by fluorescence-activated cell sort-
ing and cocultured with human myoblasts as described above.
Results (not shown) indicated that GFP cells differentiated in
coculture as efficiently as wt mesoangioblasts, whereas GFP
cells did not. Notably, no spontaneous myogenic differentiation
(i.e., without coculture) was observed under any of these con-
ditions. Overall, these data strongly suggest a crucial role of
Pax3 in the commitment of embryonic mouse mesoangioblasts
to an inducible myogenic fate.
PAX3-FKHR Mesoangioblasts Show Enhanced
Myogenic Differentiation
To further investigate the possible mechanism through
which Pax3 controls the entry of mesoangioblasts into the
myogenic program, we isolated mesoangioblasts from
PAX3PAX3-FKHR-IRESnLacZ/ mouse embryos [18]. It was shown
Figure 2. Pax3 null mesoangioblast differ-
entiation into smooth muscle and bone. (A):
Immunofluorescence analysis of Pax3 wt
and null mesoangioblasts treated with TGF
(5 ng/ml) and stained with antibody against
-smooth muscle actin (green). The nuclei
are stained with DAPI. B. RT-PCR of osteo-
genic markers expressed in Pax3 wt (wt) and
null mesoangioblasts (null) following osteo-
genic-promoting treatment. C, H2O; C,
total E10.5 embryo. (C): Von Kossa staining
of mesoangioblasts treated with BMP2 un-
der osteogenic-promoting conditions. The
percentage of Von Kossa staining is the ex-
pression of the ratio between the number of
positive osteogenic nodules and the total cell
number viewed by contrast phase. In A–D
higher magnification shows the calcified
nodules (A, C, wt; B, D, null). Abbrevi-
ations: BMP, bone morphogenic protein;
BSP, bone sialoprotein; DAPI, 4,6-dia-
midino-2-phenylindole; Osc, osteocalcin;
Osn, osteonectin; Osp, osteopontin; TGF,
transforming growth factor; wt, wild-type.
Figure 3. Alkaline phosphatase activity and adipogenic differentiation
of Pax3 null mesoangioblasts. (A): Staining for alkaline phosphatase
activity (purple cells) in Pax3 wt and Pax3 null mesoangioblasts fol-
lowing BMP2 treatment. (B): Red oil staining of Pax3 wt and null
mesoangioblasts treated with adipogenic-promoting medium. Abbrevi-
ations: BMP, bone morphogenic protein; wt, wild-type.
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previously that the oncogenic fusion protein Pax3-FKHR res-
cues the early Pax3 mutant phenotype, with overactivation of
Pax3 targets [18]. We generated both a polyclonal population
and clones from these embryos. Figure 5A shows the similar
morphology of PAX3-FKHR and Pax3 wt mesoangioblasts.
Analysis of surface markers by RT-PCR (Fig. 5B) showed no
significant differences between PAX3-FKHR and wt mesoan-
gioblasts, with the exception of the endothelial markers VE-Cad
and Tie2, which were more highly expressed in PAX3-FKHR
mesoangioblasts. We also looked for activation of MyoD and
Myf5 in the PAX3-FKHR cells, but did not observe expression at
different time points, either by Western blot or by RT-PCR (data
not shown). However, when PAX3-FKHR mesoangioblasts
were cultured in a differentiation-promoting medium, a few
cells (2%), not detected under our RT-PCR conditions, spon-
taneously differentiated as indicated by MHC expression (Fig.
5C), a phenomenon never observed with wt embryonic mesoan-
gioblasts nor with Pax3 null mesoangioblasts rescued by wt
Pax3 expression. Moreover, when either clones or polyclonal
populations of PAX3-FKHR mesoangioblasts were cocultured
with human satellite cells, they differentiated into multinucle-
ated myotubes with higher efficiency (20%–30% versus 5%–
10% in different experiments) than wt mesoangioblasts (Fig.
5D, 5E). RT-PCR using mouse-specific primers for MyoD and
myogenin transcripts confirmed this result (Fig. 5F). Differen-
tiation to other mesodermal cell types (bone, fat, smooth and
cardiac muscle) did not show differences between PAX3-FKHR
and wt cells (not shown). To discriminate between the effects
due to Pax3 and possible effects due to the FKHR moiety, the
C-terminal transcription activation domain of FKHR (FOX01A)
was also expressed in Pax3 null as well as in Pax3 wt mesoan-
gioblasts. Despite a decrease in cell proliferation, we did not
observe spontaneous muscle differentiation in either wt or Pax3
null cells (data not shown).
Therefore, these results further demonstrate the importance
of Pax3 function in mesoangioblast muscle differentiation.
Pax3 Is Required for Mesoangioblasts to Restore
-SG Synthesis in Dystrophic Mice
Finally, we examined whether the failure of Pax3 null mesoan-
gioblasts to differentiate into skeletal muscle in culture might
also prevent their ability to ameliorate the dystrophic phenotype
[2, 3] and if expression of PAX3-FKHR in these cells could
rescue this defect. Therefore, Pax3 wt, Pax3 null, and PAX3-
FKHR mesoangioblasts, previously transduced with a lentiviral
vector expressing GFP, were injected through the right femoral
artery or directly into the tibialis anterior muscle of -SG null
mice: their ability to migrate to colonize the muscle and to give
rise to -SG expressing fibers was analyzed. As shown in Figure
6A, the Pax3 null mesoangioblasts (GFP) were able to mi-
grate, cross the blood vessels, and colonize the muscles, like
Pax3 wt and PAX3-FKHR cells. However, despite their ability
to migrate to the muscle fibers (Fig. 6A), the Pax3 null mesoan-
gioblasts failed to express -SG, in contrast to wt cells (Fig.
6B–6D). More interestingly, the PAX3-FKHR cells contributed
to muscle fiber repair more efficiently than the wt cells, thus
demonstrating the role of Pax3 in mesoangioblast muscle dif-
ferentiation and in amelioration of the dystrophic phenotype.
DISCUSSION
We demonstrate that skeletal muscle differentiation of mesoan-
gioblasts in vitro and in vivo depends on Pax3. The presence of
Pax3 in multipotent mesoangioblasts does not appear to be
required for their proliferation or survival, in contrast to the
situation in myogenic progenitor cells in the embryo and adult.
Figure 4. Pax3 null mesoangioblasts fail to differentiate into skeletal muscle. (A): Skeletal muscle differentiation of Pax3 wt or null mesoangioblasts
is detected after co-cultivation with hSCs. The human nuclei are identified using an anti-human nuclei-specific antibody (lamin A/C, red) and the
expression of MHC is identified using an anti-MHC antibody (MF20, green). All the nuclei are stained with DAPI and the human nuclei appear pink
in the merged image. The white asterisks identify mouse nuclei in the myofibers. (B): The differentiated mesoangioblasts were quantified as the
number of MHC mesoangioblasts compared with the total number of mesoangioblasts in the coculture. (C): RT-PCR carried out using
mouse-specific primers for MyoD and myogenin transcripts. (D): Activity of a myogenin-lacZ reporter gene in D16 mesoangioblasts (cocultured with
C2C12 myoblasts), coexpressing either a Pax3Engr or a control (puro) vector. LacZ mRNA was analyzed by real-time RT-PCR. Abbreviations: DAPI,
4,6-diamidino-2-phenylindole; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; hSCs, human satellite cells; MHC, myosin heavy chain;
RT-PCR, reverse transcription-polymerase chain reaction; wt, wild-type.
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Differentiation of mesoangioblasts into most mesodermal deriv-
atives is also not affected by a lack of Pax3. An exception to this
are adipocytes, suggesting that this mesoangioblast derivative
may be closely linked to myogenic progenitor cells. There is
some precedent for this; Pax3 satellite cells, for example, can
assume an adipocytic phenotype [26], and in mutant embryos in
the absence of myogenic determination factors, excess adipose
tissue is observed, potentially derived from myogenic progeni-
tors [27]. In Pax3 null mesoangioblasts, cartilage/bone differ-
entiation occurs, but does not lead to alkaline phosphatase
expression, suggesting that the absence of Pax3 may have some
impact on the maturation of this phenotype. An effect on this
tissue differentiation pathway may be related to the initial ex-
pression of Pax3 in paraxial mesoderm cells that subsequently
downregulate transcription of this gene as they enter the scle-
rotome compartment and differentiate into cartilage and bone of
the vertebral column and ribs. It is also interesting to note that,
besides its expression in osteoprogenitor cells, alkaline phos-
phatase is also expressed in postnatal pericytes of striated mus-
cle [28]. This led us to identify pericytes as the postnatal
counterpart of embryonic mesoangioblasts [4]. Lack of alkaline
phosphatase expression in Pax3 null mesoangioblasts may thus
suggest that alkaline phosphatase-positive pericytes are derived
postnatally from embryonic mesoangioblasts. Unfortunately this
possibility cannot be tested in Pax3 null embryos that do not
survive the fetal stage and awaits mutant mice engineered for
time-dependent Pax3 ablation in the mesoderm.
It is striking that Pax7 is not expressed in mesoangioblasts and
that the skeletal muscle fate of these cells is Pax3, not Pax7,
dependent. Again, the analogy with what happens in the embryo is
informative. Retrospective clonal analysis and the persistence of
the Pax3-GFP reporter indicate that pericytes and smooth muscle
cells of the dorsal aorta are derived from Pax3 cells in paraxial
mesoderm that also give rise to skeletal muscle [8]. These cells that
locate to the hypaxial dermomyotome, unlike those in the central
compartment of this structure, do not express Pax7. In the chick
embryo, labeling of cells in the dermomyotome also clearly dem-
onstrates that a single Pax progenitor can give rise to both skeletal
muscle and smooth muscle of the blood vessels [7]. It is therefore
quite possible that some multipotent mesoangioblast cells in the
wall of the dorsal aorta are derived from the Pax3 multipotent
cells of the paraxial mesoderm. Interestingly, it has been reported
that Pax3 is also required for myogenic differentiation of P19
embryonal carcinoma cells, which have a spectrum of differentia-
tion options that is larger than that of mesoangioblasts [29]. Very
recently, Gang et al. [30] reported that murine mesenchymal stem
cells can also undergo myogenic differentiation when Pax3 is
overexpressed, whereas other murine cell types could not. These
data are in general agreement with our report. However, it should
be noted that in the case of mesoangioblasts, spontaneous myo-
genic differentiation does not occur and Pax3 is required to make
cells competent to respond to inductive signals from neighboring
differentiating myoblasts. Thus, these data underline a pivotal role
of Pax3 for entry into skeletal myogenesis. It is not only the dorsal
aorta that gives rise to mesoangioblasts, which can also be isolated
Figure 5. PAX3-FKHR mesoangioblasts
show robust myogenic differentiation. (A):
Phase contrast of Pax3Pax3-FKHR-IRESnlacZ/
mesoangioblasts in comparison with wt cells.
(B): RT-PCR of the markers normally ex-
pressed in wt mesoangioblasts (WT) in com-
parison with PAX3-FKHR expressing cells
(FK). (C, D): Skeletal muscle differentiation
of the PAX3-FKHR cells alone (C) or in co-
culture with hSCs (D). The human nuclei are
identified using an anti-human nuclei-specific
antibody (lamin A/C, red) and the expression
of MHC is identified using the anti-MHC an-
tibody MF20 (green). All the nuclei are stained
with DAPI and the human nuclei appear pink
in the merged image. The arrowheads indicate
mouse nuclei inside mouse only myotubes; the
asterisks identify mouse nuclei inside chimeric
myotubes also containing human nuclei from
satellite cells. (E): The differentiated mesoan-
gioblasts were quantified as the number of
MHC mesoangioblasts compared with the
total number of mesoangioblasts in the cocul-
ture. (F): RT-PCR was carried out using
mouse-specific primers for MyoD and myoge-
nin transcripts. Abbreviations: DAPI, 4,6-dia-
midino-2-phenylindole; GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase; hSCs, human
satellite cells; MHC, myosin heavy chain; RT-
PCR, reverse transcription-polymerase chain re-
action; wt, wild-type.
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from postnatal blood vessels. Pax3GFP/ expression is also ob-
served sporadically in postnatal blood vessels, suggesting that
Pax3 progenitors are still present, potentially the descendants of
multipotent Pax3 cells that had migrated from the somites to their
sites of angiogenesis during embryogenesis.
The potential therapeutic applications of mesoangioblasts
for cell therapy of muscle disease make it particularly important
to understand how their acquisition of a muscle fate is regulated.
Pax3/Pax7 alone is not sufficient to convert cells to myogenesis,
and indeed they require cofactors to function as efficient tran-
scriptional activators [6], as well as cooperation with other
upstream regulatory factors such as the homeodomain proteins
Six1/4 [31]. The signaling factors that come from differentiating
muscle cells, human satellite cells in the experiments described
here, and their regulatory targets within the mesoangioblasts
remain to be defined. However, the results reported here repre-
sent an important step forward in understanding how the me-
soangioblast cell acts as a myogenic progenitor and underlines
the essential role of Pax3/7 in directing cells into the skeletal
muscle differentiation program.
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